ReviewPharmaceutics2025
Application of Nanodrug Delivery Systems in Enhancing Treatment of Gastritis and Gastric Cancer: A Systematic Evaluation of Targeted Therapy.
Review in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- From Eradication to Holistic Regeneration: Pharmaceutics Strategies for Reshaping Gastric Homeostasis AgainstPharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
In recent years, nanomedicine has been emerging as a promising therapeutic approach in the treatment of gastritis and gastric cancer, particularly through targeted drug delivery systems and combination therapies that enhance therapeutic effects. Gastritis and gastric cancer, being common gastrointestinal diseases, often exhibit suboptimal treatment outcomes due to the limitations of traditional medications. Interventions based on nanotechnology not only improve the local concentration and bioavailability of drugs but also promote precise targeted therapy by regulating drug release rates, while minimizing adverse side effects, thereby enhancing therapeutic efficacy. Despite significant progress in basic research and preclinical applications, the clinical translation of nanomedicine still faces numerous challenges, including stability, biocompatibility, production standardization, regulatory and ethical barriers, as well as optimization of clinical trial designs. Furthermore, combining nanomedicine with other therapeutic modalities, such as immunotherapy and gene therapy, may open new avenues for addressing complex digestive system diseases. Future research should continue to explore the potential of nanocarriers, particularly in the formulation and stability of nanomaterials for precision therapy, with the aim of improving the quality of life and survival rates for patients with gastritis and gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.